Analysis of Clinical Characteristics and Medication Rationality of Polygonum Multiflorum Thunb. and Its Preparation-related Liver Injury

Abstract

Abstract: Objective To investigate the clinical characteristics of liver injury related to Polygonum multiflorum Thunb.(PM) and its common preparations, and analyze their risk factors, so as to provide reference for rational drug use in clinic. Methods Based on the cases of PM and preparation-related liver injury for the past 5 years (2012~2016), the clinical characteristics of PM-related liver injury, the rationality of drug use and possible risk factors were analyzed. Results The incidence age ranged from 8 to 93 years, and the median age of onset was 47 years (the median age of onset was 40.5 for men and 51 for women, respectively). The time span from administration to liver injury was 1~376 days, with a median of 31 days. The daily dose was 1~200 g, with a median of 10 g, suggesting that PM-induced liver injury had idiosyncratic properties. The results from further exploration of the risk factors showed that some unreasonable drug uses were important risk factors for liver injury of PM, such as individual self-medication (not under the guidance of a physician), mixed use of crude and processed PM, unconventional drug use (diet, alcohol, powder and tea) and irregular processing, etc. In addition, clinical repeated drug use, exceeding the drug instructions and inappropriate combination therapy were also important risk factors for liver injury caused by PM. Conclusion This article explores the safety risk factors of liver injury caused by PM and its preparations, suggesting that the clinical application of PM should be paid great attention to the risk of liver injury, avoid irrational use of drugs, and improve the level of safe drug use.

Key words: adverse drug reaction, Polygonum multiflorum Thunb., irrational drug use, risk factors

CLC Number:

R994.11

TU Can, GE Feilin, GUO Yuming, ZHANG Yaming, XIAO Xiaohe, WANG Jiabo. Analysis of Clinical Characteristics and Medication Rationality of Polygonum Multiflorum Thunb. and Its Preparation-related Liver Injury[J]. Chinese Journal of Pharmacovigilance, 2019, 16(5): 270-276.

References

[1] Zhu Y, Niu M, Chen J, et al.Comparison between Chinese herbal medicine and western medicine-induced liver injury of 1985 patients[J]. J Gastroenterol Hepatol, 2016, 31(8): 1476-1482
[2] 于洪礼, 于冬梅, 宋海波, 等. 何首乌及其常用制剂相关不良反应文献研究及风险因素分析[J]. 中国药物警戒, 2018, 15(8): 470-475.
[3] 秦楠,徐广,高源,等. 补骨脂异黄酮对炎症小体的调控作用及机制初探[J]. 中国药理学通报, 2019, 35(03): 364-370.
[4] 唐进法. 基于免疫应激的壮骨关节丸特异质肝损伤评价研究[D].成都: 成都中医药大学,2017.
[5] Li C Y, He Q, Gao D, et al.Idiosyncratic drug-induced liver injury linked to Polygonum multiflorum: A case study by pharmacognosy[J]. Chin J Integr Med, 2017, 23(8): 625-630.
[6] Cardenas A, Restrepo J C, Sierra F, et al.Acute hepatitis due to shen-min: a herbal product derived from Polygonum multiflorum[J]. J Clin Gastroenterol, 2006, 40(7): 629-632.
[7] Jung K A, Min H J, Yoo S S, et al.Drug-Induced Liver Injury:Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multiflorum Thunb[J]. Gut Liver, 2011, 5(4): 493-499.
[8] 国家食品药品监督管理局药品评价中心. 英国MHRA警告何首乌的肝损害不良反应[J].中国药物警戒, 2006, 3( 5) :313.
[9] CFDA. 食品药品监管总局办公厅关于修订养血生发胶囊等6 个含何首乌中药口服制剂说明书的通知[EB/OL].(2013-10-23)[2018-02-02].http://www.sfda.gov.cn/WS01/CL1706/93676.html.
[10] CFDA. 食品药品监管总局办公厅关于加强含何首乌保健食品监管有关规定的通知(食药监办食监三〔2014〕137 号)[EB/OL].(2014-07-09)[2018-02-02].http://www.sfda.gov.cn/WS01/CL0847/102806.html.
[11] CFDA. 药品不良反应信息通报(第61 期)关注口服何首乌机器成方制剂引起的肝损伤风险[EB/OL](2014-07-16)[2018- 02- 02].http://www.sfda.gov.cn/WS01/CL1989/102903.html.
[12] CFDA. 国家食品药品监管总局提示关注口服何首乌肝损伤风险[EB/OL].(2014-07-16)[2018-02-02].http://www.sda.gov.cn/WS01/CL0051/102902.html.
[13] 郭玉明, 涂灿, 何琴, 等. 基于药性功能认知的何首乌安全用药对策研究[J]. 中医杂志, 2018, 59(9): 721-724.
[14] 倪朱谟. 本草汇言[M]. 北京:中医古籍出版社, 2006: 260.
[15] 陈修园. 神农本草经读[M].北京:人民卫生出版社, 1959: 97.
[16] 涂灿, 蒋冰倩, 赵艳玲, 等. 何首乌炮制前后对大鼠肝脏的损伤比较及敏感指标筛选[J].中国中药杂志, 2015, 40(4): 654-660.
[17] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J]. 实用肝脏病杂志, 2017, 20(2): 257-274.
[18] 肖小河, 李秀惠, 朱云, 等. 中草药相关肝损伤临床诊疗指南[J]. 中国中药志, 2016, 41(7):1165-1172.
[19] 肖小河,唐健元,茅益民,等.中药药源性肝损伤临床评价技术指导原则[J].药学学报,2018,53(11):1931-1942.
[20] 杨倩,李晓宇,赵新妹,等.含何首乌的中成药不良反应系统分析[J].中草药,2017,48(9):1878-1887.
[21] Navarro V J, Khan I, Bjornsson E, et al.Liver injury from herbal and dietary supplements[J]. Hepatology, 2017, 65(1): 363-373.
[22] 王伽伯, 柏兆方, 肖小河, 等. 基于整合证据链的中草药肝毒性客观辨识与合理用药:以何首乌为例[J]. 科学通报, 2016, 61(9):971-980.
[23] Wang J B, Ma Z J, Niu M, et al.Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum[J]. Front Med, 2015, 9(4): 457-467.
[24] Wang J B, Zhu Y, Bai Z F, et al.Guidelines for the Diagnosis and Management of Herb-Induced Liver Injury[J]. Chin J Integr Med, 2018, 24(9):696-706.
[25] 张乐, 柏兆方, 李春雨, 等. 制首乌中顺式二苯乙烯苷转化量与特异质肝损伤的相关性研究[J]. 药学学报, 2017, 52(7): 1041-1047.
[26] 李瑞煜, 冯五文, 李晓菲, 等. 金属离子对何首乌中二苯乙烯苷稳定性的影响[J].药学学报, 2016, 51(1): 116-121.
[27] 王伽伯, 张乐, 肖小河, 等. 基于多因子组合模型评价何首乌肝损伤易感性的方法及应用: 中国, CN107633869A[P].2018-01-26.
[28] 李春雨, 李晓菲, 涂灿, 等. 基于内毒素模型的何首乌特异质肝损伤评价[J].药学学报,2015, 50(1) : 28-33.
[29] 王伽伯, 张乐, 肖小河, 等. 中药药源性肝损伤因果关系的评价策略和方法[J].药学学报,2018,53(6):920-928.
[30] 柏兆方, 高源, 左晓彬, 等. 免疫调控与特异质型药物性肝损伤发生机制研究进展[J]. 药学学报, 2017, 52(7): 1019-1026.
[31] 王伽伯,崔鹤蓉,柏兆方,等.精准医学下的中药安全性评价策略和方法:病证毒理学[J].药学学报,2016,51(11):1681-1688.
[32] Xiao X H, Tang J Y, Mao Y M, et al.Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury Issued by China Food and Drug Administration[J]. Acta Pharmaceutica Sinica B, 2018,12(3):2-8.